L29 Antivirals

Question 1

Enfuvirtide disease

Answer 1

HIV

Question 2

Enfuvirtide path

Answer 2

blocks refolding of gp41

Inhibits membrane fusion for ENTRY

Question 3

Amantadine disease

Answer 3

infuenza

Question 4

Amantadine path

Answer 4

blocks M2 ion channel

preventing nucleocapsid release at end of ENTRY (uncoating)

Question 5

Rimantadine disease

Answer 5

influenza

Question 6

Rimantadine path

Answer 6

blocks M2 ion channel

preventing nucleocapsid release at end of ENTRY (uncoating)

Question 7

Acyclovir disease

Answer 7

herpes

Most effective against HSV1,2

Question 8

Acyclovir type

Answer 8

nucleoside analogue preventing REPLICATION (nucleic acid synthesis)

Question 9

Acyclovir specificity depends on

Answer 9

Virus thymadine kinase

Question 10

Ganciclovir disease

Answer 10

CMV

Question 11

Gangciclovir vs Acyclovir

Answer 11

Works on CMV but more toxic due to cellular kinases

Question 12

Valganciclovir vs Acyclovir

Answer 12

Both treat HSV but has improved bioavailability

Question 13

Acyclovir hurdles

Answer 13

Bioavailability

Specificiity on virus Thymadine Kinase

Question 14

Foscarnet disease

Answer 14

Herpes

Question 15

Foscarnet path

Answer 15

Prevent viral polymerase activity preventing REPLICATION (nucleic acid synthesis)

Question 16

Foscarnet downfalls

Answer 16

IV administration

Toxic

Question 17

Nucleoside inhibitors for HIV and HepB negatives

Answer 17

Toxic
Resistance
Usually includes more than one

Question 18

Ribavarin disease

Answer 18

RNA viruses

Question 19

Ribavarin mechanisms

Answer 19

Triphosphate inhibits polymerase
Monophasphate inhibits inosine monophosphate dh
Impaires capping of mRNA

Question 20

Ritonavir disease

Answer 20

HIV

Question 21

Ritonavir path

Answer 21

Block Gag-Pol cleavage
Boosts protease inhibitors
Prevents PROTEASE (late protein processing)

Question 22

How to prevent virus release

Answer 22

Neuraminidase inhibitors

Question 23

Bioavailability components

Answer 23

Absorption into body
Transport to site
Intake by cell
Half life

Question 24

Neuraminidase inhibitor disease

Answer 24

Influenza..virus release

Question 25

Interferons are more effective against ___ than ____

Answer 25

RNA viruses than DNA viruses

Question 26

Killed vaccine disadvantages

Answer 26

does not induce cell mediated immunity protection is shorter usually injected

Question 27

Polio vaccine complication

Answer 27

Vaccine acquired paralytic poliomyelitis VAPP | We only use the killed vaccine

Question 28

Immune cells important for vaccination

Answer 28

B cells CD8 T-cells CD4 T-cells

Question 29

Vaccines utilizing B cells only

Answer 29

``` pneumonococcal Influenza B (HIB) ```

Question 30

Vaccines utilizing B and T cell including ____

Answer 30

Including IgA Influenza Polio Oral typhoid